KIT and gastrointestinal stromal tumor: The identification of KIT and PDGFRA activating mutations1,2 as the central oncogenic drivers in GIST has transformed GIST from an untreatable, highly fatal disease to a paradigmatic disease for the impact of targeted treatments, such as imatinib3–5.